Does the recombinant shingles vaccine cause fatigue, headache, and fever that disrupt daily activities?
What the Evidence Shows
We analyzed the available evidence and found that about 1 in 6 people who receive the recombinant shingles vaccine report fatigue, headache, or fever that may interfere with their normal daily activities the next day [1]. This pattern was reported in 78 studies or assertions, while 39 others did not find the same link.
The evidence we’ve reviewed leans toward these side effects being relatively common, though not universal. For some, the symptoms are mild and short-lived, lasting only a day or two. For others, they can be strong enough to affect work, exercise, or routine tasks. These reactions are not signs of the vaccine causing shingles — they are the body’s normal response to building immunity.
We did not find evidence that these symptoms last longer than a few days or lead to lasting health issues. The fact that nearly 40 studies did not report these effects suggests the experience varies from person to person. Some may feel nothing, while others notice a clear but temporary disruption.
What this means for most people is that if you get the recombinant shingles vaccine, it’s reasonable to plan for a day of rest afterward — especially if you’ve had similar reactions to other vaccines in the past. There’s no need to avoid the vaccine because of these effects, but it’s smart to schedule your shot when you don’t have important commitments the next day.
Evidence from Studies
The recombinant shingles vaccine causes systemic reactions such as fatigue, headache, and fever in approximately one in six recipients, sufficient to disrupt daily activities the following day.
RECOMBINANT HERPES ZOSTER VACCINE (RZV) IN A LARGE COHORT OF AUTOIMMUNE RHEUMATIC DISEASES PATIENTS: A PROSPECTIVE DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED PHASE 4 STUDY
DOI: 10.3899/jrheum.2025-0390.pt005
Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial.
DOI: 10.1016/j.vaccine.2025.126819
Recombinant Herpes Zoster Vaccine in Immunosuppressed Rheumatology Patients: Real-World Safety Data from a Prospective Cohort Study in Saudi Arabia
DOI: 10.4103/ara.ara_29_25
Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis
DOI: 10.1136/bmj.k4029
A prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the recombinant zoster vaccine in Chinese adults ≥50 years of age
DOI: 10.1080/21645515.2024.2439031
Update History
- May 28, 2026New topic created from assertion